knowledge -WSS

knowledge

author：entertainment 2025-09-29 17:02:01 - browse：86

Principal Deputy FDA Commissioner Janet Woodcock Stefani Reynolds/The New York Times via AP

WASHINGTON — Principal Deputy FDA Commissioner Janet Woodcock will retire early next year from the Food and Drug Administration after helping steer the agency through an historic period of medical advances during nearly four decades in key leadership positions, she confirmed to STAT Thursday.

Woodcock, a doctor with a chemistry degree, joined FDA in 1986 at its biologics center, where she oversaw the approval of the first biotechnology-based treatments for multiple sclerosis and cystic fibrosis. In 1994, she was named director of the drug center, where she played a key role in guiding some of the most impactful changes to the regulation of medicine, according to Trump administration FDA Commissioner Scott Gottlieb.

Woodcock envisioned that antibody drugs would become a backbone of therapy and created a more predictable regulatory path for their review and approval, Gottlieb said. She presided over a major expansion and modernization of the generic drug program, standardizing reviews in a way that allowed the industry to become safer and more robust, and crafted the reform of over-the-counter drug reviews.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Morphosys mixed study results for blood cancer drug

WSS

Threats against the LGBTQIA+ community intensifying: Department of Homeland Security

Iowa House, Senate pass 6

Lecanemab for Alzheimer's is coming. Is the health system ready?

Palantir health business leans on meeting customers’ needs

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

NYU radiologists take on the challenge of expensive MRI machines

leisure time

knowledge

focus

Cancer drug shortages should be causing more outrage

Astellas still sees hope in its gene therapy after four deaths

George Santos makes 1st court appearance after pleading not guilty to 13 counts

It's time to get medical device identifiers over the finish line

Hollywood unions extend contract negotiations for actors

A new study sees potential in DNA sequencing of infants

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

NYU radiologists take on the challenge of expensive MRI machines

United colonoscopy coverage change 'may cost lives,' doctors say

Morphosys mixed study results for blood cancer drug

focus

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Congress must reauthorize a committee to support older Americans

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Living with Fabry disease, a condition that causes chronic pain

Why medical students are struggling with mental health

It's time to get medical device identifiers over the finish line

knowledge

explore

entertainment

hotspot